Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March
2019
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Filing of Form 20-F
with SEC
6 March 2019 07:00 GMT
FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND
EXCHANGE COMMISSION
AstraZeneca PLC (the Company) announced today that, on 5
March 2019, it filed its 2018 Annual Report on Form 20-F with the
US Securities and Exchange Commission (SEC). The document is
available for viewing on the SEC website
at www.sec.gov and
also on the Company's website at www.astrazeneca.com.
The Company will send any holder of the Company's securities, upon
request, a hard copy of the Company's complete audited financial
statements free of charge. Requests may be made by writing to the
Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge, CB2 0AA,
UK.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please
visit astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media Relations
|
|
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203 749 5916
|
|
Rob
Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203 749 5906
|
|
Jennifer
Hursit
|
UK/Global
|
+44 203 749 5762
|
|
Christina
Malmberg Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
|
|
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer
Gruvris
|
BioPharma - Cardiovascular; Metabolism
|
+44 203 749 5711
|
|
Nick
Stone
|
BioPharma - Respiratory; Renal
|
+44 203 749 5716
|
|
Josie
Afolabi
|
Other
|
+44 203 749 5631
|
|
Craig
Marks
|
Finance; Fixed Income
|
+44 7881 615 764
|
|
Jennifer
Kretzmann
|
Retail Investors; Corporate Access
|
+44 203 749 5824
|
|
US
toll-free
|
|
+1 866 381 72 77
|
|
|
|
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
06 March
2019
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|